WEST CHESTER, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced third quarter 2015 financial results.
“We are pleased with our performance in the third quarter and excited about our prospects for sustained growth,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “With our recent release of CryoForm in the EU, our acquisition of nContact and our strong product and clinical pipeline, we are well positioned to continue addressing the large and expanding market opportunities ahead of us. We remain focused on our goal of expanding treatment of atrial fibrillation and improving patients’ lives.”
Help employers find you! Check out all the jobs and post your resume.
“We are pleased with our performance in the third quarter and excited about our prospects for sustained growth,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “With our recent release of CryoForm in the EU, our acquisition of nContact and our strong product and clinical pipeline, we are well positioned to continue addressing the large and expanding market opportunities ahead of us. We remain focused on our goal of expanding treatment of atrial fibrillation and improving patients’ lives.”
Help employers find you! Check out all the jobs and post your resume.
